Adaptyx is a healthtech company focused on addressing critical gaps in health monitoring through its aptamer-based wearable sensors. Spun out of Dr. Tom Soh’s lab at Stanford University, Adaptyx’s proprietary platform uses real-time, multi-biomarker tracking to provide actionable insights for managing chronic conditions like heart failure and diabetes.
With a strong patent portfolio and a team of experts in biosensing and healthcare technology, Adaptyx is strategically positioned to deliver cutting-edge solutions for both clinical and at-home care. By targeting high-impact use cases, Adaptyx aims to improve patient outcomes, reduce hospital readmissions, and expand access to precision health monitoring.
As healthcare increasingly shifts toward precision and preventative care, Adaptyx’s technology is well-positioned to lead in both clinical and at-home monitoring. With a strong foundation in Stanford research, a robust patent portfolio, and a clear regulatory pathway, Adaptyx is set up for scalable growth in a high-demand sector.
With a strong patent portfolio and a team of experts in biosensing and healthcare technology, Adaptyx is strategically positioned to deliver cutting-edge solutions for both clinical and at-home care. By targeting high-impact use cases, Adaptyx aims to improve patient outcomes, reduce hospital readmissions, and expand access to precision health monitoring.
As healthcare increasingly shifts toward precision and preventative care, Adaptyx’s technology is well-positioned to lead in both clinical and at-home monitoring. With a strong foundation in Stanford research, a robust patent portfolio, and a clear regulatory pathway, Adaptyx is set up for scalable growth in a high-demand sector.
Investors 2
| Date | Name | Website |
| 14.04.2025 | Seaside Ve... | seasideven... |
| 23.12.2024 | Overwater ... | overwater.... |
Mentions in press and media 1
| Date | Title | Description |
| 20.10.2025 | Adaptyx Raises $14M in Seed Financing | Adaptyx Biosciences, a Menlo Park, CA-based biowearables company developing a platform for continuous, multi-analyte molecular monitoring, raised $14m in seed financing, bringing total funding to $23m since inception. The round was led by I... |